Tardan Francois - 04 Aug 2025 Form 4 Insider Report for NV5 Global, Inc. (NVEE)

Role: Director
Signature: /s/ MaryJo OBrien, as attorney in fact
Issuer symbol: NVEE
Transactions as of: 04 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 06 Aug 2025, 18:18:51 UTC
Previous filing: 04 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Francois Tardan	Director	200 SOUTH PARK RD., SUITE 350, HOLLYWOOD	/s/ MaryJo OBrien, as attorney in fact	06 Aug 2025	0001632505

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVEE	Common Stock	Disposed to Issuer		-29,704	-100%		0	04 Aug 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Tardan Francois is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to the Agreement and Plan of Merger, dated as of May 14, 2025 (the "Merger Agreement"), by and among NV5 Global, Inc. (the "Company"), Acuren Corporation ("Acuren"), Ryder Merger Sub I, Inc. and Ryder Merger Sub II, Inc., each outstanding share of common stock of the Issuer was converted into the right to receive 1.1523 shares of Acuren common stock per share and $10.00 in cash per share (together, the "Merger Consideration"). In addition, pursuant to the Merger Agreement, any outstanding restricted stock units of NV5 held by the Reporting Person automatically vested in full in accordance with its terms immediately prior to the effective time of the mergers and converted into the right to receive the Merger Consideration, less applicable tax withholdings.

Content

Pursuant to the Agreement and Plan of Merger, dated as of May 14, 2025 (the "Merger Agreement"), by and among NV5 Global, Inc. (the "Company"), Acuren Corporation ("Acuren"), Ryder Merger Sub I, Inc. and Ryder Merger Sub II, Inc., each outstanding share of common stock of the Issuer was converted into the right to receive 1.1523 shares of Acuren common stock per share and $10.00 in cash per share (together, the "Merger Consideration"). In addition, pursuant to the Merger Agreement, any outstanding restricted stock units of NV5 held by the Reporting Person automatically vested in full in accordance with its terms immediately prior to the effective time of the mergers and converted into the right to receive the Merger Consideration, less applicable tax withholdings.